CareDx Partners with TC BioPharm: A Strategic Step for TuanChe in Hematology Oncology

A Strategic Leap in Hematology Oncology: CareDx Partners with TC BioPharm

CareDx, Inc., a prominent player in precision medicine and healthcare solutions for transplant patients, announces a strategic partnership with TC BioPharm to conduct pharmacokinetic analysis using its AlloCell™ solution in the ACHIEVE clinical trial. This collaboration marks a significant advancement in the treatment landscape for blood cancers, particularly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). CareDx, headquartered in Brisbane, California, focuses on enhancing the quality of care for transplant patients and caregivers through innovative genomic testing and solutions.

The ACHIEVE trial is an adaptive, open-label Phase II study that assesses the efficacy of TCB008, an allogeneic gamma-delta T-cell therapy. This trial is particularly noteworthy as it incorporates CareDx's AlloCell solution, which has previously been utilized in ten clinical trials. The AlloCell test is designed to evaluate the expansion and persistence of TCB008 within enrolled patients, offering critical insights into its impact on the patients' immune systems. Marica Grskovic, PhD, Chief Strategy Officer at CareDx, expresses excitement about this venture into hematology oncology, highlighting the potential of allogeneic cell therapy to improve outcomes for AML patients.

Alison Bracchi, Executive Vice President of Clinical Operations at TC BioPharm, underscores the importance of this collaboration for the development of TCB008. By leveraging CareDx's expertise and innovative solutions, the partnership aims to enhance treatment options for patients battling challenging hematological conditions. The integration of the AlloCell solution into the ACHIEVE trial not only strengthens the clinical evaluation of TCB008 but also reinforces CareDx’s commitment to providing comprehensive testing services throughout the transplant journey. This strategic move consolidates CareDx's leadership position in genomics-based information for transplant patients while expanding its reach into the critical area of hematology oncology.

In addition to its focus on blood cancers, CareDx continues to prioritize the delivery of high-value solutions for transplant patients. The company's robust suite of testing services reflects its dedication to improving patient care and outcomes. The partnership with TC BioPharm is a pivotal step that highlights the evolving landscape of cancer treatment and the role of precision medicine in addressing unmet medical needs. As the trial progresses, the collaboration is poised to yield valuable data that could reshape therapeutic approaches for AML and MDS, ultimately benefiting patients and caregivers alike.